Navigation Links
Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
Date:7/15/2008

the identified bacteria were reported directly to the treating clinicians whereas for patients in the Usual Care group, data were entered into the hospital's laboratory information system as usual. Medical records of enrolled patients were analyzed for demographics, comorbid conditions, location within the hospital, antimicrobial use, length of hospitalization, mortality, and other factors to understand the impact of the rapid PNA FISH results on patient care and outcomes. Significant comparison results for the two groups are listed below.

Comparison of Data for Notification of PNA FISH (NPF) group vs. Usual Care (UC) group

-- Total of 202 patients enrolled in study; 101 in NPF group vs. 101 in UC group

-- 61 patients with S. aureus; 32 in NPF group vs. 29 in UC group

-- 141 patient with CoNS; 69 in NPF vs. 72 in UC group

-- 44 patients in ICU vs. 158 in non-ICU

-- 53% reduction in overall mortality; 8 deaths in NPF group vs. 17 deaths in UC group

-- 80% reduction in mortality rate for intensive care unit (ICU) patients; 10% (2 deaths) for NPF group vs. 48% (11 deaths) for UC group

-- 82% reduction in mortality rate for ICU patients with S. aureus; 10% for NPF group vs. 56% for UC group

-- 67% reduction in median antibiotic use after notification of results; median of 1 day for NPF group vs. 3 days for UC group

-- 100% reduction in median antibiotic use for CoNS patients after notification of; 0 days for NPF group vs. 2.5 days for UC group

-- Trend toward $19,441 reduction in median hospital charges; $72,932 median charges for NPF group vs. $92,373 for UC group

"Rapid delivery of PNA FISH data from the laboratory to treating clinicians was associated with reduced mortality in ICU patients," said lead author Shmuel Shoham, M.D., Section of Infectious Diseases and Director of Transplant Infectious Diseases at Washington Hospital Center. "There was also a trend toward reduced length of
'/>"/>

SOURCE AdvanDx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
2. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
5. Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU
6. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
7. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
8. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... LAIYANG, China , May 17 /PRNewswire-Asia-FirstCall/ -- ... pharmaceutical company with its principal operations in the People,s,Republic ... quarter,fiscal year 2010 ended March 31, 2010 . , ... -- Revenue was $25.6 million, a slight decrease of 0.6% ...
... Connecticut waterways may be safer from biomedical waste, thanks to ... CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community and ... to a West Haven company that stems improper disposal of needles ... West Haven ...
Cached Medicine Technology:Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 2Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 3Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 4Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 5Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 6Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 7Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 8Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 9Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 10Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 11Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 12Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 13Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 14Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 15Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 16Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 17Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 18Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 19Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 20Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 21West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2
(Date:9/19/2014)... Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, ... in the Journal of the National Cancer Institute ... melanoma. , "For the first time, we have established ... play a part in the risk of developing melanoma," ... School of Medicine at the University of Leeds (UK). ...
(Date:9/19/2014)... 2014 According to a report from ... blood-thinner Xarelto, named as defendants in several lawsuits filed ... moved the court to dismiss those suits because the ... connection with Philadelphia.* The cases include, for instance, Fontan ... Pa. Comm. Pls., Philadelphia Cty.), which was brought by ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... News) -- The U.S. Food and Drug Administration approved a ... part of a class of once-a-week injectable drugs that help ... "Trulicity is a new treatment option, which can ... control blood sugar levels in the overall management of type ... Office of Drug Evaluation II, said in an agency news ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... North Carolina in Chapel Hill that was published in the ... two genes - C282Y and H63D, which are linked to ... increased risk of developing colon cancer. For the research, the ... which, more than 400 already had colon cancer, and were ...
... at Trinity College, Dublin, Ireland, have found from a ... arterial stiffness after smoking even one cigarette in both ... effects of smoking on large artery properties in 185 ... years. 116 non-smokers// were compared with 41 chronic smokers ...
... have traditionally been treated by removing a disc or placing ... together. Now, an artificial disc which is being studied as ... phase one study that was recently completed compared the prosthesis ... patients// were randomized, with one having a fusion operation for ...
... is being reassessed to find out if it could again ... and leprosy. The drug which is unlicensed in Europe was ... morning// sickness. However, it was banned after mothers who took ... for the Evaluation of Medicinal Products (EMEA) is now considering ...
... among children that were known until now were chickenpox, ... neurologists have found that stroke is also among one ... go unnoticed. A National Hospital's database analysis by Dr. ... California showed that four in 1000 newborns had a ...
... recent health survey across England showed that many do ... cancer and other serious diseases. The survey included nearly// ... trends were revealed by the study. ,The survey ... eating and household income. Almost 40% of women in ...
Cached Medicine News:Health News:Artificial discs available as replacements for damaged discs 2Health News:Stroke also in list of common childhood ailments 2
... The MICROM CTM 6 is a highly efficient ... and Cytology laboratories. The instrument is capable ... with continuous slide rack loading capabilities. The slide ... 30 slides each. User intuitive operation is made ...
... Miniaturized robotic system for spinal procedures. The ... a highly accurate, easy-to-use solution that enables ... and minimum intervention. SpineAssist currently answers a ... use guidance devices in pedicle screw insertion ...
... The SENSAR® Acrylic IOL with OptiEdge offers ... long-term refractive stability, and excellent handling. The ... had no reports of vacuoles; the patented ... reflections and provide 360 degrees of contact ...
ACRYSOF® Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are inten...
Medicine Products: